Xtant, a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced the commercial launch of CollagenX, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.
CollagenX is a potential addition to every case type currently addressed by Xtant’s biologics portfolio, as well as procedures performed in other surgical disciplines.
Sean Browne, President and CEO of Xtant Medical, stated, “The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, we are uniquely equipped to deliver the quality and consistency that can significantly improve patient outcomes.”
Xtant, a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced the commercial launch of CollagenX, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical...
Xtant, a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced the commercial launch of CollagenX, its bovine collagen particulate product for surgical wound closure designed to promote healing, prevent dehiscence, and help mitigate concerns related to surgical site infections.
CollagenX is a potential addition to every case type currently addressed by Xtant’s biologics portfolio, as well as procedures performed in other surgical disciplines.
Sean Browne, President and CEO of Xtant Medical, stated, “The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients. As one of the few fully vertically integrated regenerative medicine firms, we are uniquely equipped to deliver the quality and consistency that can significantly improve patient outcomes.”
Copy to clipboard 
